A view of immune reprogramming from ASH
ASH abstracts reveal new mechanisms and consequences of immune cell repolarization in hematology
ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors.
Strategies to convert immunosuppressive macrophage and T cell subsets into proinflammatory cells are gaining momentum as a way to simultaneously release the brakes and rev up the gas for antitumor immunity (see "Flipping the Switch in Immuno-oncology").
The approach has primarily been framed as a way to reprogram the microenvironment in solid tumors, but abstracts released ahead of the 2019 meeting of the American Society of Hematology (ASH) shine a light on immune polarization in hematological cancers and other blood disorders.
Presentations from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) and others suggest macrophage and T cell reprogramming contribute to therapeutic responses to inhibitors